Is Gilead Sciences Inc (NASDAQ:GILD)’s Idelalisib Free From The Trial Phase?

Posted by Michael Korte October 11, 2013 0 Comment 2230 views


Gilead Sciences, Inc (NASDAQ:GILD) has stalled the idelalisib Phase-III clinical-trial before the scheduled date. This is due to the fact that an Independent Data-monitoring Committee has taken an interim peek at the study data and has shown that the idelalisib, the company’s PI3k-delta inhibitor in conjunction with Rituxan by Roche was working more effectively than the latter by itself. This was being used in patients who had been previously treated for chronic lymphocytic leukemia.

The norm is that Data Monitoring Committees recommend the early end of trails in the event that there is unequivocal-evidence that the medication is working. In such cases, it is not ethical to continue the trial with a group that is also receiving an inferior drug-regimen. Now that the trail has come to an end, the patients who choose to be treated with idelalisib can get the opportunity to do so.

Thursday’s trading

In Thursday’s trading, Gilead Sciences, Inc (NASDAQ:GILD) rose by 6.52%. The opening price of the shares was $61.63, which climbed to an intraday high of $62.80 and dipped to a close of $62.74. Approximately 15.24 million shares were traded on Thursday while an average volume of 6.67 million shares were traded over a 30 day period. The 52-week low of Gilead Sciences, Inc (NASDAQ:GILD) shares is $32.07 and its 52-week high is $64.74. The company has a market capitalization of $96.03 billion.

About the company

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based bio-pharma company. It is involved in discovering, developing and commercializing medicines. It focuses on areas such as human immunodeficiency virus (AIDS), liver diseases like hepatitis-B and C and metabolic or respiratory conditions. Gilead Sciences, Inc (NASDAQ:GILD) has operations in North America, Asia Pacific and Europe. It’s products include Truvada, ,Atripla, Complera/Eviplera, Tamiflu Viread, Hepsera, Letairis, Emtriva, Ranexa, Lexiscan/Rapiscan, Vistide, Macugen, AmBisome, Cayston.



About Michael Korte

Michael Korte an investigative reporter at GDP Insider and is a breaking news reporter. Michael work includes investigations of misconduct by federal prosecutors and industrial air pollution around the nation's schools. His reporting has been recognized with the Hillman Prize for Newspaper Journalism, the Grantham Prize for Excellence in Reporting on the Environment, and the Philip Meyer Journalism Award for reporting that incorporates social science methods.

View all post by Michael Korte Visit author's website

Write Your Comment